Cas:154938-68-8 3-[1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]propanoic acid manufacturer & supplier

Chemical Name:3-[1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]propanoic acid

CAS.NO:154938-68-8

Synonyms:n-fmoc-4-piperidinepropionic acid

Molecular Formula:C₂₃H₂₅NO₄

Molecular Weight:379.44900

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:66.84000

Exact Mass:379.17800

LogP:4.45020

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like n-fmoc-4-piperidinepropionic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-fmoc-4-piperidinepropionic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-fmoc-4-piperidinepropionic acid Use and application,n-fmoc-4-piperidinepropionic acid technical grade,usp/ep/jp grade.

Related News: For example, an active ingredient to relieve pain is included in a painkiller. 3-[1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]propanoic acid manufacturer The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 3-[1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]propanoic acid supplier Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. 3-[1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]propanoic acid vendor Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. 3-[1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]propanoic acid factory Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).